CVRx Q4 revenue $7.2M (+96% YoY); guides FY2023 revenue $35-38M

CVRx, Inc.

2022-FY EPS reported -$2.02 revenue$22,469,000

Q4 2022 total revenue $7.2M, up 96% vs prior year; US HF revenue $6.0M (+121% YoY).
Full year 2022 revenue $22.5M (+72% YoY); net loss $41.4M ($2.02 per share).
Active implanting centers grew 130% to 106 in 2022 from 46 in 2021.
FY2023 guidance: revenue $35-38M, gross margin 78-79%, operating expenses $76-80M.
BeAT-HF trial unblinding and data announcement expected later in Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CVRx, Inc. reported financial results for the fourth quarter and full year of 2022.

Period: the fourth quarter and full year of 2022
Result: reported results

Exact text from the filing

On January 26, 2023, CVRx, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2022. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

View on SEC.gov

53 earnings releases filed in the last 30 days. Browse all earnings releases →

CVRx, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-007029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.